NYU Ovarian Cancer Early Detection Program Blood and Genetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

890 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-06-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Improving current strategies for detection of early stage disease can impact favorably on long-term survival of women with ovarian cancer. To reduce the morbidity and mortality of ovarian cancer, screening for this disease must detect early stage disease rather than advanced stage disease. Thus the challenge for the future is to identify and develop highly sensitive and specific tumor markers that can be applied to population-based screening for the early detection of ovarian cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

NCT01187602

Ovarian Cancer

UNKNOWN

A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration

NCT06564428

Ovarian Neoplasms

RECRUITING

Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients

NCT04537702

Ovarian Cancer, Epithelial Peritoneal Cancer Fallopian Tube Cancer

COMPLETED NA

Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease

NCT05212779

Epithelial Ovarian Cancer

ACTIVE_NOT_RECRUITING

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

NCT03614689

Ovarian Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of NYU Ovarian Cancer Early Detection Program is to establish an effective, early detection program employing state-of-the-art science and technology in collaboration with other nationally recognized clinicians and scientists.

This proposed research study will foster collaboration between clinicians and scientists that will facilitate the rapid identification of a set of molecular, biochemical, functional, and genetic markers which can be employed to effectively detect and manage ovarian cancer and other gynecological malignancies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NYU OCEDP Population

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Women enrolled in the NYU Ovarian Cancer Early Detection Program have at least one of the following risk factors:

* A personal history of breast cancer
* One or more first degree relatives (mother, sister, daughter) with ovarian cancer
* Multiple family members with either breast and/or ovarian cancer
* A personal history of a positive BRCA1 or BRCA2 genetic test result
* A close relative with a positive BRCA1 or BRCA2 genetic test result
* A personal history of colon or endometrial cancer with at least two relatives with a Lynch/HNPCC-associated cancer (colorectal, endometrial, small bowel, ureter, or renal pelvis cancer)
* Synchronous or metachronous endometrial and colorectal cancer
* A personal history of a mismatch repair gene mutation (MLH1, MSH2, MSH6 or PMS2)
* A close relative with a mismatch repair gene mutation (MLH1, MSH2, MSH6 or PMS2)
* A personal history of colorectal or endometrial cancer with a mismatch repair defect (ie. Microsatellite instability (MSI) or immunohistochemical loss of expression of MLH1, MSH2, MSH6, or PMS2)
* The use of fertility drugs for more than one year

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No